{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:04:22Z","timestamp":1764079462631,"version":"3.40.5"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the safety and efficacy of maintenance therapy with the oral proteasome inhibitor ixazomib in patients with newly diagnosed multiple myeloma (NDMM) not undergoing transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were pooled from four NDMM phase I\/II studies; patients received induction therapy with once\u2010 or twice\u2010weekly ixazomib plus lenalidomide\u2010dexamethasone (IRd), melphalan\u2010prednisone (IMP), or cyclophosphamide\u2010dexamethasone (ICd), followed by single\u2010agent ixazomib maintenance, given at the last tolerated dose during induction, until disease progression, death, or unacceptable toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 121 patients achieved stable disease or better after induction (weekly IRd, n\u00a0=\u00a025; twice\u2010weekly IRd, n\u00a0=\u00a018; weekly or twice\u2010weekly IMP, n\u00a0=\u00a035; weekly ICd, n\u00a0=\u00a043) and received\u00a0\u2265\u00a01 dose of ixazomib maintenance. Grade\u00a0\u2265\u00a03 drug\u2010related adverse events occurred in 24% of patients during maintenance; each event was reported in \u22642% of patients. Rates of complete response were 22% after induction and 35% after maintenance. A total of 28 patients (23%) improved their response during maintenance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ixazomib maintenance following ixazomib\u2010based induction is associated with deepening of responses and a positive safety profile with no cumulative toxicity in patients with NDMM not undergoing transplantation, suggesting that ixazomib is feasible for long\u2010term administration. Phase III investigation of ixazomib maintenance is ongoing.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13231","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T17:23:22Z","timestamp":1554312202000},"page":"494-503","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I\/II studies"],"prefix":"10.1111","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics National and Kapodistrian University of Athens Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Asunci\u00f3n","family":"Echeveste Gutierrez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Donostia San Sebasti\u00e1n Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Grzasko","sequence":"additional","affiliation":[{"name":"Department of Hematology St. John\u2019s Cancer Center and Medical University of Lublin Lublin Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[{"name":"The Ohio State University Columbus Ohio"},{"name":"Winship Cancer Institute of Emory University Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus F.","family":"San\u2010Miguel","sequence":"additional","affiliation":[{"name":"Clinica Universidad de Navarra, Centro Investigaci\u00f3n Medica Aplicada (CIMA) IDISNA, CIBERONC Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Labotka","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc. Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vickie","family":"Lu","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc. Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Berg","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc. Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catriona","family":"Byrne","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc. Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyang","family":"Teng","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc. Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohui","family":"Liu","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc. Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi","family":"van de Velde","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc. Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,5,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.211"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-427815"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402888"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.35"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2466"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.7295"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2835-3"},{"key":"e_1_2_9_12_1","unstructured":"Revlimid EU SmPC.2017.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000717\/WC500056018.pdf. Accessed January 2019."},{"key":"e_1_2_9_13_1","unstructured":"Revlimid US Highlights of Prescribing Information.2017.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021880s049lbl.pdf. Accessed January 2019."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.7934"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1344212"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.23"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2644-6"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-496"},{"key":"e_1_2_9_21_1","unstructured":"Millennium Pharmaceuticals Inc.NINLARO\u00ae (ixazomib) capsules for oral use. United States Prescribing Information.2016.https:\/\/www.ninlaro.com\/downloads\/prescribing-information.pdf. Accessed January 2019."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14733"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15394"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.185991"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.011"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0384-1"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"issue":"2","key":"e_1_2_9_32_1","first-page":"142","article-title":"Deep and durable responses with weekly ixazomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma: long\u2010term follow\u2010up of patients who did not undergo SCT","volume":"102","author":"Kumar S","year":"2017","journal-title":"Haematologica"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.01.008"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.7618"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0023"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13231","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T10:59:28Z","timestamp":1694343568000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,8]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/ejh.13231"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13231","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2019,5,8]]},"assertion":[{"value":"2019-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}